No-Spa (Drotaverine Hydrochloride)

Drotaverine Hydrochloride works by inhibiting the enzyme phosphodiesterase‑4, which raises intracellular cyclic AMP levels in smooth‑muscle cells. The increase in cAMP reduces calcium entry into the cells, leading to relaxation of the muscle fibers and a decrease in spasm without significant anticholinergic activity.

The appropriate dose of No-Spa is determined by a qualified healthcare professional based on the individual’s condition, age, weight and overall health. Prescribers set the dosage and frequency according to clinical guidelines and patient response, and patients should follow the prescribed regimen exactly.

Safety data for drotaverine hydrochloride in pregnancy and lactation are limited, and the product is generally classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing No‑Spa to pregnant or nursing women.

To order No‑Spa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

No‑Spa (drotaverine) differs from anticholinergic agents like hyoscine by acting primarily through phosphodiesterase‑4 inhibition rather than blocking muscarinic receptors. This mechanism often results in fewer anticholinergic side effects such as dry mouth or blurred vision, while providing comparable relief of smooth‑muscle spasm.

No‑Spa tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

No‑Spa is administered orally, typically as a tablet that is swallowed with water. The exact method of administration, including whether it should be taken with or without food, is determined by the prescribing clinician based on the patient’s specific therapeutic needs.

Serious but rare risks of No‑Spa include severe allergic reactions such as rash, swelling or Stevens‑Johnson syndrome, significant drops in blood pressure, cardiac arrhythmias, liver enzyme elevations and blood‑cell abnormalities like neutropenia. Patients should seek immediate medical attention if any of these symptoms occur.

No‑Spa should be avoided in individuals with known hypersensitivity to drotaverine or any of its excipients, in patients with severe renal impairment without dose adjustment, and in those taking contraindicated medications such as potent CYP3A4 inhibitors or other antispasmodics unless supervised by a physician.